ELI LILLY & Co (LLY) operating KPIs
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly cOVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 30 | -97.2% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 387 | +78.1% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 129 | -13.3% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,470 | +81.5% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,060 | +21.7% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 217 | – | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 149 | – | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 810 | – | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 871 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | – | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 0 | – | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | – | Form 10-Q (filed 2021-04-30) ↗ |
Breakdown
What makes up covid-19 antibodies (bamlanivimab / etesevimab / bebtelovimab) — worldwide revenue ($m) [legacy separate disclosure]
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy]0 · Q4 2023
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Outside U.S. revenue ($M) [legacy]0 · Q4 2023
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy]-100.0% · Q4 2023
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M), quarterly Q1 2020–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_covid19antibodies_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.